In fiscal year 2025, NeoImmuneTech (950220) reported revenue of 66,673 KRW.
Income Statement
| Year | Revenue | Op Profit | Net Income | Source |
|---|---|---|---|---|
| 2025 | 66,673 KRW | -18 million KRW | -22 million KRW | [source] |
| 2024 | 124,917 KRW | -29 million KRW | -30 million KRW | [source] |
| 2023 | — | -43 million KRW | -41 million KRW | [source] |
| 2022 | — | -45 million KRW | -47 million KRW | [source] |
| 2021 | — | -45 million KRW | -46 million KRW | [source] |
Balance Sheet
| Year | Total Assets | Total Liabilities | Total Equity | Source |
|---|---|---|---|---|
| 2025 | 51 million KRW | 15 million KRW | 37 million KRW | [source] |
| 2024 | 41 million KRW | 14 million KRW | 27 million KRW | [source] |
| 2023 | 71 million KRW | 11 million KRW | 61 million KRW | [source] |
| 2022 | 110 million KRW | 14 million KRW | 96 million KRW | [source] |
| 2021 | 160 million KRW | 18 million KRW | 141 million KRW | [source] |
This company has no revenue account in the DART financial statements. Industry-specific accounts such as insurance or interest income are not converted to revenue.